Biopharmaceuticals: the economic equation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

As more biopharmaceuticals reach the market, more attention will be given to issues such as cost-effectiveness evaluations, biosimilars, and price controls. The value biologic therapies bring to the healthcare system may take years to appreciate in full -perhaps only when policy decisions allow for their economic effects to be understood.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Biotechnol Healthc

Title: Biotechnology healthcare

Publisher:

ISSN: 1554-169X

ISSN (Print): 1554-169X

Publication date (Electronic): Dec 2007

Volume: 4

Issue: 6

Affiliations

[1 ] Erwin A. Blackstone, PhD, is a professor of economics at Temple University in Philadelphia. Joseph P. Fuhr Jr., PhD, is a professor of economics at Widener University, in Chester, Pa., and an adjunct research professor for the Department of Health Policy, Thomas Jefferson University, in Philadelphia.

Article

PMC ID: 2651729

PubMed ID: 22478688

SO-VID: 3d907e79-17c1-4609-974f-da68bb284acd

History

Data availability:

Comments

Comment on this article

Cited by 2

See all cited by